In:
Transplant Infectious Disease, Wiley, Vol. 18, No. 2 ( 2016-04), p. 202-209
Kurzfassung:
Intestinal and multivisceral transplantation can be complicated by cytomegalovirus ( CMV )‐related viremia and disease. Intravenous ganciclovir ( GCV ) and oral valganciclovir remain the treatment of choice in this setting. Limited data are available on GCV ‐resistant ( GCV ‐R) CMV infection in small intestine and multivisceral transplant recipients. Method A retrospective review was performed on all patients who underwent small intestine or multivisceral transplantation from November 8, 2003 through November 30, 2008. Those with CMV viremia and invasive disease were identified. GCV resistance was suspected in patients who continued to have viremic episodes or invasive disease despite appropriate GCV treatment. Genotypic analyses were performed to detect the presence of GCV resistance genes UL 97 and UL 54. Results During the study period, 88 small intestine or multivisceral transplants were performed on 85 patients. Of the 88 transplantations, 16 patients developed CMV viremia with or without end‐organ disease (18.2%) and 5.7% developed GCV ‐R CMV infection. In patients diagnosed with CMV infection, 31.3% (5/16) had GCV ‐R CMV infection. Of patients with GCV ‐R CMV infection, 80% (4/5) developed CMV allograft enteritis, resulting in allograft explantation in 3 patients. All patients with GCV ‐R CMV infection were CMV donor positive/recipient negative. Patients with tissue‐invasive CMV disease were 18 times more likely to be infected with GCV ‐R CMV (95% confidence interval 1.24–260.93; P ‐value 0.0341). Conclusion Small intestinal and multivisceral transplant recipients have a higher rate of GCV ‐R CMV infection compared with other solid organ transplant recipients, which is often associated with tissue‐invasive disease and allograft loss.
Materialart:
Online-Ressource
ISSN:
1398-2273
,
1399-3062
DOI:
10.1111/tid.2016.18.issue-2
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2016
ZDB Id:
2010983-0
Bookmarklink
